SINT vs. PAVM, GCTK, SONX, INBS, LUCY, STSS, BIOL, AVGR, TNON, and BBLG
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include PAVmed (PAVM), GlucoTrack (GCTK), Sonendo (SONX), Intelligent Bio Solutions (INBS), Innovative Eyewear (LUCY), Sharps Technology (STSS), BIOLASE (BIOL), Avinger (AVGR), Tenon Medical (TNON), and Bone Biologics (BBLG). These companies are all part of the "medical equipment" industry.
PAVmed (NASDAQ:PAVM) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Sintx Technologies has a net margin of -318.99% compared to Sintx Technologies' net margin of -2,037.67%. Sintx Technologies' return on equity of 0.00% beat PAVmed's return on equity.
19.9% of PAVmed shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 12.6% of PAVmed shares are owned by insiders. Comparatively, 1.0% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
PAVmed currently has a consensus target price of $21.00, indicating a potential upside of 1,979.21%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe PAVmed is more favorable than Sintx Technologies.
In the previous week, PAVmed and PAVmed both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.94 beat PAVmed's score of 0.93 indicating that PAVmed is being referred to more favorably in the media.
Sintx Technologies has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
PAVmed has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
PAVmed received 165 more outperform votes than Sintx Technologies when rated by MarketBeat users. Likewise, 65.90% of users gave PAVmed an outperform vote while only 61.02% of users gave Sintx Technologies an outperform vote.
Summary
PAVmed beats Sintx Technologies on 11 of the 17 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sintx Technologies Competitors List
Related Companies and Tools